The series is stated in the current share scale after splits; dividends are not included in the price
West Pharmaceutical makes stoppers and seals for vials of injectable medicines.
A rubber stopper costs a fraction of a percent of a drug's price but stays in contact with it for years: it must neither leach impurities nor absorb the active ingredient. The material is registered together with the medicine, and changing supplier means repeating regulatory procedures — which is almost never done.
Hence a position rare even among suppliers: price does not decide, and demand follows the number of doses produced. The growth of injectable medicines — biologics, vaccines, weight-loss drugs — works directly in the company's favour. Risks: capital spending on new lines, customer inventories after the pandemic surge and currency rates. The dividend is token.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
West Pharmaceutical Services, Inc. (WST) is a company in the Health care sector; its shares trade on NYSE.
The price of West Pharmaceutical Services, Inc. (WST) on November 2, 2026 is 411.96 $, −0.16 % on the day. Over the past year the price changed by +45.66 %. The P/E ratio is 51.17, which is above the sector median (24.61). Market capitalization is 28.90 billion $, rank 7 among 100 stocks of the same industry with a known capitalization.
West Pharmaceutical Services, Inc. trades on NYSE under the ticker WST. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks WST has traded between 223.83 $ and 386.00 $. As of 2 November 2026 the price stood 98.16 % of the way from the 52-week low to the high.
Over one year WST shares rose 45.66 %; over six months they rose 41.96 %. Volatility over 90 days is 24.98 %. Dividends are not included: this is price change only, as of 2 November 2026.
WST trades at a price-to-earnings ratio of 51.2, above the sector median of 24.6. Price to sales is 8.7, above the sector median of 3.6. Price to book is 9.7, above the sector median of 2.5. Calculated from reports for the period ending 30 June 2026.
West Pharmaceutical Services, Inc. reported revenue of 3.3B $ and net income of 565M $ over the last four quarters. Net margin is 16.98 %. Revenue changed by +12.38 % year over year. Earnings per share are 7.81 $. Market capitalisation is 28.9B $.
WST has a return on equity of 18.89 %, above the sector median of −40.58 %. Return on assets is 13.86 %, above the sector median of −30.08 %. Operating margin is 20.45 %, above the sector median of −20.96 %.
